Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes

Medicine & Life Sciences

• dulaglutide 100%
• Immunoglobulin Fc Fragments 80%
• Immunoglobulin Fragments 73%
• Glucagon-Like Peptide 1 67%
• Type 2 Diabetes Mellitus 43%
• glucagon-like peptide 1 (7-37) 13%
• Dipeptidyl Peptidase 4 9%
• Therapeutics 9%
• Glucose 9%
• Equidae 8%
• Phase II Clinical Trials 8%
• Phase III Clinical Trials 8%
• C-Peptide 8%
• Glycated Hemoglobin A 7%
• Insulin Secretion 7%
• Antibody Formation 6%
• Immunoglobulin G 5%
• Pharmacokinetics 5%
• Body Weight 5%
• Placebos 4%
• Insulin 4%
• Clinical Trials 4%
• In Vitro Techniques 3%

Chemical Compounds

• Glucagon-Like Peptide 1 91%
• Insulin Derivative 29%
• Insulinotropic 24%
• C-Peptide 22%
• Clarification 18%
• Hemoglobin 13%
• Pharmacokinetics 10%
• Glucose 10%
• Plasma 8%
• Weight 7%
• Reduction 6%